Leerink Partnrs Weighs in on Immunocore Q2 Earnings

Immunocore Holdings plc (NASDAQ:IMCR) – Stock analysts at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for shares of Immunocore in a research note issued on Wednesday, February 26th. Leerink Partnrs analyst J. Chang expects that the company will post earnings per share of ($0.39) for the quarter. The consensus estimate for Immunocore’s current full-year earnings is ($0.94) per share. Leerink Partnrs also issued estimates for Immunocore’s Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.41) EPS and FY2026 earnings at ($2.38) EPS.

IMCR has been the topic of a number of other research reports. Mizuho lowered shares of Immunocore from an “outperform” rating to a “neutral” rating and cut their price objective for the stock from $72.00 to $38.00 in a research report on Monday, November 11th. HC Wainwright reissued a “buy” rating and set a $100.00 price target on shares of Immunocore in a research report on Monday, January 27th. Needham & Company LLC restated a “buy” rating and issued a $71.00 price objective on shares of Immunocore in a report on Friday, January 10th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $35.00 target price (down previously from $74.00) on shares of Immunocore in a report on Friday, December 13th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $65.64.

Immunocore Stock Up 5.3 %

Shares of Immunocore stock opened at $30.77 on Thursday. Immunocore has a 52-week low of $27.69 and a 52-week high of $72.56. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. The business’s 50 day simple moving average is $30.03 and its 200 day simple moving average is $31.96. The firm has a market cap of $1.54 billion, a PE ratio of -32.39 and a beta of 0.77.

Institutional Investors Weigh In On Immunocore

Hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP boosted its stake in Immunocore by 10.5% in the 3rd quarter. Wellington Management Group LLP now owns 7,048,833 shares of the company’s stock valued at $219,430,000 after purchasing an additional 668,382 shares during the period. Groupama Asset Managment bought a new stake in shares of Immunocore in the fourth quarter valued at about $17,700,000. Primecap Management Co. CA grew its stake in shares of Immunocore by 26.7% in the third quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company’s stock valued at $76,954,000 after acquiring an additional 520,950 shares in the last quarter. Deep Track Capital LP acquired a new position in shares of Immunocore in the fourth quarter valued at about $15,322,000. Finally, Tang Capital Management LLC increased its position in Immunocore by 40.7% during the fourth quarter. Tang Capital Management LLC now owns 1,555,600 shares of the company’s stock worth $45,890,000 after acquiring an additional 450,000 shares during the period. 84.50% of the stock is currently owned by institutional investors and hedge funds.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.